Review of esomeprazole in the treatment of acid disorders

Bibliography

• SANDLER RS, EVERHART JE, DONOWITZ M et al.: The burden of selected digestive diseases in the United States. Gastroenterology (2002) 122:1500–1511.
   PubMed Web of Science ®Google Scholar
• HOLLENZ M, STOLTE M, LABENZ J:Prevalence of gastro-oesophageal reflux disease in general practice. Dtsch. Med. Wochensch. (German) (2002) 127:1007–1012.
   PubMed Web of Science ®Google Scholar
• DIPALMA JA: Management of severe gastroesophageal reflux disease. J. Clin. Gastroenterology (2001) 32:19–26.
   PubMed Web of Science ®Google Scholar
• NANDURKAR S, TALLEY NJ: Epidemiology and natural history of reflux disease. Baillieres Best Pract. Res. Clin. Gastroenterol (2000) 14:743–757.
   PubMed Web of Science ®Google Scholar
• HORN J: The proton-pump inhibitors: similarities and differences. Clin. Ther: (2000) 22:266–280.
   PubMed Web of Science ®Google Scholar
• LAI KC, LAM SK, CHU KM et al: Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl. J. Med. (2002) 346:2033–2038.
   PubMed Web of Science ®Google Scholar
• AGRAWAL NM, CAMPBELL DR, SAFDI MA, LUKASIK NL, HUANG B, HABER MM: Superiority of lansoprazole versus ranitidine in healing nonsteroidalanti- inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch. Intern. Med. (2000) 160:1455–1461.
   PubMed Web of Science ®Google Scholar
• JOHNSON DA, BENJAMIN SB, VAKIL NB et al.: Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am. Gastroenterol (2001) 96:27-34.A pivotal trial that demonstrated that use of esomeprazole 20 mg as a maintenance therapy effectively controlled heartburn symptoms and prevented relapse in 90% of patients with GERD.
   Google Scholar
• VAKIL NB, SHAKER R, HWANG C, D'AMICO D, HAMELIN B: The new proton pump inhibitor esomeprazole is effective as maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment. Pharmacol Ther. (2001) 15:927–935.
   PubMed Web of Science ®Google Scholar
• JUUL-HANSEN P, RYDNING A, DITLEF JACOBSEN C, HANSEN T: High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand. Gastroenterol (2001) 36:806–810.
   PubMed Web of Science ®Google Scholar
• FASS R, OFMAN JJ, SAMPLINER RE, CAMARGO L, WENDEL C, FENNERTY MB: The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment. Pharmacol Ther. (2000) 14:389–396.
   PubMed Web of Science ®Google Scholar
• GALMICHE JP: How do we offer clinical relief to patients with gastro-oesophageal reflux disease? Eur. Gastroenterol Hepatol (2000) 12 (Suppl. 1):53–56.
   Google Scholar
• DEVAULT KR, CASTELL DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am.j Gastroenterol (1999) 94:1434–1442.
   PubMed Web of Science ®Google Scholar
• O'CONNOR JB, PROVENZALE D, BRAZER S: Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am. J. Gastroenterol (2000) 95:3356–3364.
   PubMed Web of Science ®Google Scholar
• DENT J: Management of reflux disease. Gut (2002) 50\(Suppl. 4):67–71.
   Google Scholar
• DENT J, JONES R, KAHRILAS P, TALLEY NJ: Management of gastro-oesophageal reflux disease in general practice. Br. Med. J. (2001) 322:344–347.
   PubMed Web of Science ®Google Scholar
• CRAWLEY JA, SCHMITT CM: How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J. Clin. Outcomes Manag. (2000) 7:29–34.
   Google Scholar
• SCOTT LJ, DUNN CJ, MALLARKEY G, SHARPE M: Esomeprazole: a review of its use in the management of acid-related disorders in the US. Drugs (2002) 62:1091–1118.
   PubMed Web of Science ®Google Scholar
• HASSAN-ALIN M, NIAZI M, ROHSS K, LANGERSTROM P-0: Esomeprazole, the ..Cisomer of omeprazole is optically stable in humans. Gastroenterology (2000) 118:A1244.
   Google Scholar
• ANDERSSON T, ROHSS K,BREDBERG E, HASSAN-ALIN M: Pharmacokinetics and pharmacodynamics of esomeprazole, the Sisomer of omeprazole. Aliment. Pharmacol Ther: (2001) 15:1563–1569.
   PubMed Web of Science ®Google Scholar
• •This study reported that thepharmacokinetics of esomeprazole are time and dose dependent, and that a good correlation exists between AUC and effect with esomeprazole. The data suggested that there is an increased acid inhibitory effect with esomeprazole relative to omeprazole.
   Google Scholar
• CASTELL DO, KAHRILAS PJ,RICHTER JE et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am.j Gastroenterol (2002) 97:575–583.
   Google Scholar
• ••A pivotal trial that enrolled 5000patients and demonstrated that esomeprazole 40 mg o.d. is more effective than lansoprazole 30 mg o.d. in healing erosive esophagitis and resolving heartburn in patients with erosive esophagitis.
   Google Scholar
• KAHRILAS PJ, FALK GW,JOHNSON DA et al.: Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment. Pharmacol Ther. (2000) 14:1249–1258.
   Google Scholar
• ••This randomized clinical trial recruitedalmost 2000 patients and provided evidence that esomeprazole is more effective than omeprazole in healing and symptom resolution in patients with reflux esophagitis. The tolerability profile of esomeprazole was similar to that of omeprazole.
   Google Scholar
• RICHTER JE, KAHRILAS PJ,JOHANSON J et al.: Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am.j Gastroenterol (2001) 96:656–665.
   Google Scholar
• Nexiume [prescribing information].Wilmington (DE): AstraZeneca LP, 2003.
   Google Scholar
• ZIMMERMANN AE: Esomeprazole: a novel proton pump inhibitor for the treatment of acid-related disorders. Formulary (2000) 35:882–893.
   Google Scholar
• HUANG J-Q, HUNT R: Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physician. Baillieres Best Piaci Res. Clin. Gastroenterol (2001) 15:355–370.
   PubMed Web of Science ®Google Scholar
• HASSAN-ALIN M, ANDERSSON T, BREDBERG E, ROHSS K: Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur. Clin. Pharmacol (2000) 56:665–670.
   Web of Science ®Google Scholar
• ANDERSSON T, HASSAN-ALIN M, HASSELGREN G, ROHSS K,WEIDOLF L: Pharmacokinetic studies with esomeprazole, the 0-isomer of omeprazole. Clin. Pharmacokinet. (2001) 40:411–426.
   PubMed Web of Science ®Google Scholar
• LANGTRY HD, MARKHAM A: Rabeprazole, a review of its use in acid-related gastrointestinal disorders. Drugs (1999) 58:725–742.
   PubMed Web of Science ®Google Scholar
• LANGTRY HD, WILDE MI: Omeprazole. A review of its use in Helicobacterinfection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs (1998) 56:447–486.
   Google Scholar
• LANGTRY HD, WILDE MI: Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs (1997) 54:473–500.
   PubMed Web of Science ®Google Scholar
• ABEL() A, ANDERSSON TB, ANTONSSON M, NAUDOT AK, SKANBERG I, WEIDOLF L: Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. (2000) 28:966–972.
   PubMed Web of Science ®Google Scholar
• HORAI Y, KIMURA M, FURUIE H et al: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment. Pharmacol Ther. (2001) 15:793–803.
   PubMed Web of Science ®Google Scholar
• SAITOH T, FUKUSHIMA Y, OTSUKA H et al.: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol Ther. (2002) 16:1811–1817.
   PubMed Web of Science ®Google Scholar
• ANDERSSON T, MAGNER D, PATEL J, ROGERS P, LEVINE JG: Esomeprazole 40 mg capsules are bioequivalent whenadministered intact or as the contents mixed with applesauce. Clin. Drug Invest. (2001) 21:67–71.
   Web of Science ®Google Scholar
• JOHNSON DA, ROACH A:Esomeprazole pellets are stable following In vitro suspension in common beverages. Am.j Gastroenterol (2002) 97(9):520.
   PubMed Web of Science ®Google Scholar
• SOSTEK MB, CHEN Y, SKAMMER W, WINTER H, ZHAO J, ANDERSSON T: Esomeprazole: nasogastric tube administration of the contents of an opened capsule suspended in water compared with oral administration in healthy volunteers. Am. J. Gastroenterol (2002) 97:S23.
   Web of Science ®Google Scholar
• WHITE CM, KALUS JS, QUERCIA R et al.: Esomeprazole capsule contents suspended in water can be efficiently delivered through nasogastric and gastrostomy tubes. Am. J. Health Syst. Pharm. (2002) 59:2085–2088.
   PubMed Web of Science ®Google Scholar
• LIND T, RYDBERG L, KYLEBACK A et al.: Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol Ther: (2000) 14:861–867.
   PubMed Web of Science ®Google Scholar
• SJOVALL H, BJORNSSON E, HOLMBERG J, HASSELGREN G, ROHSS K, HASSAN-ALIN M: Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Ear. Gastroenterol Hepatol (2002) 14:491–496.
   PubMed Web of Science ®Google Scholar
• HUNT RH: Importance of pH control inthe management of GERD. Arch. Intern. Med. (1999) 159:649–657.
   PubMed Web of Science ®Google Scholar
• WILDER-SMITH C, ROHSS K, LUNDIN C, RYDHOLM H: Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology(2000) 118:A–22.
   PubMed Web of Science ®Google Scholar
• WILDER-SMITH C, CLAAR-NILSSON C, HASSELGREN G, ROHSS K: Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. Am. I Gastroentera (2001) 96(Suppl.):45.
   Google Scholar
• THOMSON ABR, CLAAR-NILSSON C, HASSELGREN G, NIAZI M, ROHSS K: Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration. Gut (2000) 47(Suppl. III):63.
   Google Scholar
• ROHSS K, HASSELGREN G, HEDENSTROM H: Effect of esomeprazole 40 mg versus omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig. Dis. Sci. (2002) 47:954–958.
   PubMed Web of Science ®Google Scholar
• WILDER-SMITH C, ROHSS K, CLAAR-NILSSON C, HASSELGREN G: Esomeprazole 20 mg provides faster and more effective acid control than lansoprazole 15 mg.V Gut (2000) 47(Suppl. III):62–63.
   Google Scholar
• WILDER-SMITH C, ROHSS K, CLAAR-NILSSON C, RYDHOLM H: Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg. Gut (2000) 47(Suppl. III):A–63.
   Google Scholar
• WILDER-SMITH C, ROHSS KM, CLAAR-NILSSON C, LUNDIN C: Esomeprazole 40mg provides faster and more effective acid control than lansoprazole 30 mg in patients with symptoms of gastroesophageal reflux disease. Gastroenterology (2002) 122(Suppl. I):200.
   Google Scholar
• MATON P, VAKIL NB, LEVINE JG, HWANG C, SKAMMER W, LUNDBORG P: Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Sal: (2001) 24:625–635.
   PubMed Web of Science ®Google Scholar
• PrilosecTM [prescribing information]. Wilmington DE: AstraZeneca LP, 2003.
   Google Scholar
• LAURITSEN K, JUNGHARD 0, EKLUND S: Esomeprazole 20mg compared with lansoprazole 15mg for maintenance therapy in patients with healed erosive esophagitis. Gastroenterology (2002) 122:A199.
   Web of Science ®Google Scholar
• ••An important randomized trial thatconcluded that esomeprazole 20 mg o.d. is more effective than lansoprazole 15 mg o.d. for maintaining healed erosive esophagitis and controlling accompanying GERD symptoms.
   Google Scholar
• TULASSAY Z, KRYSZEWSKI A, DITE P et al.: One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur: .1. Gastroenterol Hepatol (2001) 13:1457–1465.
   Google Scholar
• LAINE L, FENNERTY MB, OSATO M et al.: Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Gastroenterol (2000) 95:3393–3398.
   Web of Science ®Google Scholar
• VELDHUYZEN VAN ZANTEN S, LAURITSEN K, DELCHIER JC et al: One-week triple therapy with esomeprazoleprovides effective eradication of Helicobacter pylori in duodenal ulcer disease. Ailment. Pharmacol Ther: (2000) 14:1605–1611.
   Google Scholar
• ROACH AC, HWANG C,BJORKMAN DJ: Evidence-based analysis of the benefit of esomeprazole in the treatment of erosive oesophagitis (EE). Gut (2001) 49 (Suppl. III):A2755.
   Google Scholar
• VAKIL NB, RICHTER JE, HWANG C,MARINO V, LEVINE J: Does baseline severity of EE impact healing with esomeprazole? Am. J. Gastroenterol (2000) 95:2439.
   Google Scholar
• RICHTER JE, PEURA D,BENJAMIN SB, JOELSSON B, WHIPPLE J: Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch. Intern. Med. (2000) 160:1810–1816.
   PubMed Web of Science ®Google Scholar
• JOHNSON DA, VAKIL NB, HWANG C, LEVINE JG: Absence of symptoms in erosive esophagitis (EE) patients treated with esomeprazole is a highly reliable indicator of healing. Gastroenterology (2001) 120(5 Suppl. 1):A2237.
   Google Scholar
• LAURITSEN K, JUNGHARD 0, EKLUND S, WIKLUND I: The effect of esomeprazole 40 mg on healing, reflux symptoms and quality of life in patients with reflux esophagitis. Gastroenterology (2002) 122:A200.
   Web of Science ®Google Scholar
• KATZ PO, CASTELL DO, MARINO V, WHIPPLE J, LEVINE JG: Comparison of the new PPI esomeprazole, the Sisomer of omeprazole, versus placebo for the treatment of symptomatic GERD (sGERD). Am. J. Gastroenterol (2000) 95:2424–2425.
   Google Scholar
• HASSELGREN B, CLAAR-NILSSON C, HASSELGREN G, NIAZI M, SVERNHAGE E: Studies in healthy volunteers do not show any electrocardiographic effects with esomeprazole. Clin. Drug. Invest. (2000) 20:425–431.
   Web of Science ®Google Scholar
• ANDERSSON T, HASSAN-ALIN M, HASSELGREN G, ROHSS K: Drug interaction studies with esomeprazole, the 0-isomer of omeprazole. Clin. Pharmacokinet. (2001) 40:523–537.
   PubMed Web of Science ®Google Scholar
• Aciphex® [prescribing information]. Teaneck NJ: Eisai, Inc. (2003).
   Google Scholar
• Prevacide [prescribing information]. Lake Forest IL: TAP Pharmaceuticals, Inc. (2003).
   Google Scholar